Alzheimer's disease is one of the most prevalent neurodegenerative diseases. The most accepted theory assumes that the formation of amyloid-beta plaques is the causative process of the onset and development of the disease. However, until today, post-mortem brain analysis remains the only certain way to diagnose the disease. Therefore, there is a need to detect amyloid-beta plaques in the early stages of the disease to be able to properly design therapeutic strategies. Here, several analogues of Tc-99m have been designed to detect amyloid-beta plaques with medical imaging techniques. The results show that one of these complexes was able to bind to amyloid-beta plaques in samples of human frontal cortex from patients with Alzheimer's disease. This can open the door to a reliable, easy source of imaging agents that can pave the road to an early diagnosis and follow-up of Alzheimer's disease.
Rhenium(i) complexes of N-heterocyclic carbene ligands that bind to amyloid plaques of Alzheimer's disease
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!